drugset / Trial / NCT00396318

A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

NCT00396318

Phase 3 Completed 251 enrolled Genentech, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study and treated with one or two doses of tenecteplase.

Timeline

Start
2006-12
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 2 mg Other

Indications

No indication recorded.